Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer

• Published in: Molecular medicine (Cambridge, Mass.) Vol. 28; no. 1; pp. 1 - 20
• Main Authors: Lin, Ruo-Kai, Su, Chih-Ming, Lin, Shih-Yun, Thi Anh Thu, Le, Liew, Phui-Ly, Chen, Jian-Yu, Tzeng, Huey-En, Liu, Yun-Ru, Chang, Tzu-Hao, Lee, Cheng-Yang, Hung, Chin-Sheng
• Format: Journal Article
• Language: English
• Published: London BioMed Central 17.06.2022; BMC
• Subjects: Biobanks; Biomarkers; Biomedical and Life Sciences; Biomedicine; Breast cancer; Cancer therapies; Circulating cell-free DNA; Disease progression; DNA methylation; Endocrine therapy; Epidermal growth factor; Epigenetics; Estrogens; Hospitals; Metastasis; Molecular Medicine; Plasma; Proteins; Research Article; Science; Software; TMEM240; Tumor suppressor genes; Tumors; South Korea; United Kingdom > UK; Germany; Taiwan; Circulating cell-free DNA; Cell motility; RNA-seq; Disease progression; DNA methylation; Tumor suppressor genes; Breast cancer; Proliferation; TMEM240; MetaCore and hormone therapy
• ISSN: 1076-1551; 1528-3658; 1528-3658
• DOI: 10.1186/s10020-022-00474-9

Background Approximately 25% of patients with early-stage breast cancer experience cancer progression throughout the disease course. Alterations in TMEM240 in breast cancer were identified and investigated to monitor treatment response and disease progression. Methods Circulating methylated TMEM240 in the plasma of breast cancer patients was used to monitor treatment response and disease progression. The Cancer Genome Atlas (TCGA) data in Western countries and Illumina methylation arrays in Taiwanese breast cancer patients were used to identify novel hypermethylated CpG sites and genes related to poor hormone therapy response. Quantitative methylation-specific PCR (QMSP), real-time reverse transcription PCR, and immunohistochemical analyses were performed to measure DNA methylation and mRNA and protein expression levels in 394 samples from Taiwanese and Korean breast cancer patients. TMEM240 gene manipulation, viability, migration assays, RNA-seq, and MetaCore were performed to determine its biological functions and relationship to hormone drug treatment response in breast cancer cells. Results Aberrant methylated TMEM240 was identified in breast cancer patients with poor hormone therapy response using genome-wide methylation analysis in the Taiwan and TCGA breast cancer cohorts. A cell model showed that TMEM240, which is localized to the cell membrane and cytoplasm, represses breast cancer cell proliferation and migration and regulates the expression levels of enzymes involved in estrone and estradiol metabolism. TMEM240 protein expression was observed in normal breast tissues but was not detected in 88.2% (67/76) of breast tumors and in 90.0% (9/10) of metastatic tumors from breast cancer patients. QMSP revealed that in 54.5% (55/101) of Taiwanese breast cancer patients, the methylation level of TMEM240 was at least twofold higher in tumor tissues than in matched normal breast tissues. Patients with hypermethylation of TMEM240 had poor 10-year overall survival ( p  = 0.003) and poor treatment response, especially hormone therapy response ( p  < 0.001). Circulating methylated TMEM240 dramatically and gradually decreased and then diminished in patients without disease progression, whereas it returned and its levels in plasma rose again in patients with disease progression. Prediction of disease progression based on circulating methylated TMEM240 was found to have 87.5% sensitivity, 93.1% specificity, and 90.2% accuracy. Conclusions Hypermethylation of TMEM240 is a potential biomarker for treatment response and disease progression monitoring in breast cancer.